Organovo Holdings Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Feb 10

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Aug 24

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

May 10

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

Jan 04

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

May 28

CEO

Organovo Holdings heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Keith Murphy	Executive Chairman & Corporate Secretary	4.3yrs	US$789.99k	0.80% $ 51.7k
Thomas Hess	President & CFO	3.1yrs	US$199.32k	geen gegevens
Vaidehi Joshi	Director of Discovery Biology & Director	2.6yrs	US$119.05k	0.26% $ 16.5k
Curtis Tyree	Senior Vice President of Strategy & Business Development	2.8yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ONVO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Keith Murphy	Executive Chairman & Corporate Secretary	4.3yrs	US$789.99k	0.80% $ 51.7k
Vaidehi Joshi	Director of Discovery Biology & Director	2.7yrs	US$119.05k	0.26% $ 16.5k
Adam Stern	Independent Director	4.3yrs	US$124.15k	0.26% $ 16.5k
Alison Milhous	Independent Director	4.2yrs	US$132.25k	0.26% $ 16.5k
Douglas Cohen	Lead Independent Director	4.2yrs	US$132.25k	0.33% $ 21.5k
David Gobel	Independent Director	4.2yrs	US$132.25k	0.13% $ 8.2k

4.2yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ONVO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Organovo Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

High number of new and inexperienced directors

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

High number of new and inexperienced directors

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Recent updates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd